Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E; PROLONG-9FP Investigator Study Group..

Thromb Haemost. 2016 Sep 27;116(4):659-68. doi: 10.1160/TH16-03-0179.

2.

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH; Hemophilia Inhibitor Research Study Investigators..

J Thromb Haemost. 2016 Oct;14(10):1931-1940. doi: 10.1111/jth.13438.

PMID:
27501440
3.

Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.

Ramakrishnan R, Balu-Iyer SV.

J Pharm Sci. 2016 Oct;105(10):3039-45. doi: 10.1016/j.xphs.2016.06.008.

PMID:
27431011
4.

Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report.

Doma SA, Hillarp A, Pajič T, Andoljšek D, Černelč P, Preldžnik Zupan I.

Biochem Med (Zagreb). 2016;26(2):279-84. doi: 10.11613/BM.2016.033.

5.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I; AFFINITY Investigators..

Blood. 2016 Aug 4;128(5):630-7. doi: 10.1182/blood-2016-01-687434.

6.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Álvarez-Roman MT, Voigt C, Blackman N, Jacobs I; PROLONG-9FP Investigators Study Group..

Blood. 2016 Apr 7;127(14):1761-9. doi: 10.1182/blood-2015-09-669234.

7.

Improving the performance of factor VIII inhibitor tests in hemophilia A.

Miller CH.

Thromb Res. 2015 Dec;136(6):1047-8. doi: 10.1016/j.thromres.2015.09.019. No abstract available.

8.

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F.

J Clin Invest. 2015 Oct 1;125(10):3766-81. doi: 10.1172/JCI81859.

9.

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A; AICE Working Group..

Blood Transfus. 2015 Jul;13(3):498-513. doi: 10.2450/2015.0141-15. No abstract available.

10.

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.

Hyun SY, Park SY, Lee SY, Kook H, Paik SH, Jang IJ, Lee KS.

Yonsei Med J. 2015 Jul;56(4):935-43. doi: 10.3349/ymj.2015.56.4.935.

11.

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.

Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, Jacobs I, Wuerfel T, Santagostino E.

Haemophilia. 2015 Nov;21(6):784-90. doi: 10.1111/hae.12721.

12.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Oldenburg J, Lacroix-Desmazes S, Lillicrap D.

Haematologica. 2015 Feb;100(2):149-56. doi: 10.3324/haematol.2014.112821. Review.

13.
14.

The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P, Kasatkar P, Gaikwad T, Ali S, Jadli A, Patil R, Parihar A, Shanbhag S, Kulkarni B, Ghosh K, Shetty S.

Indian J Hematol Blood Transfus. 2014 Dec;30(4):356-63. doi: 10.1007/s12288-014-0342-z.

15.

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators.; Hemophilia Inhibitor Research Study Investigators..

J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768.

16.

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C; paradigm 2 Investigators..

Blood. 2014 Dec 18;124(26):3880-6. doi: 10.1182/blood-2014-05-573055.

17.

A public health approach to the prevention of inhibitors in hemophilia.

Soucie JM, Miller CH, Kelly FM, Oakley M, Brown DL, Kucab P.

Am J Prev Med. 2014 Nov;47(5):669-73. doi: 10.1016/j.amepre.2014.07.007.

18.

Illustrated operative management of spontaneous bleeding and compartment syndrome of the lower extremity in a patient with acquired hemophilia A: a case report.

Jentzsch T, Brand-Staufer B, Schäfer FP, Wanner GA, Simmen HP.

J Med Case Rep. 2014 Apr 30;8:132. doi: 10.1186/1752-1947-8-132.

19.

Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.

Sakurai Y, Takeda T.

J Immunol Res. 2014;2014:320674. doi: 10.1155/2014/320674.

20.

National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting.

Soucie JM, Miller CH, Kelly FM, Aschman D, DiMichele D, Konkle BA, Kulkarni R, Monahan PE; CDC Inhibitor Surveillance Working Group..

Am J Hematol. 2014 Jun;89(6):621-5. doi: 10.1002/ajh.23704.

Items per page

Supplemental Content

Support Center